EDITORS' RECOMMENDATIONS
NICE, France — After years of disappointing trials of monoclonal antibodies directed against forms of β-amyloid for the treatment of Alzheimer's disease (AD), one appears to have hit the mark, at least in early stages of the disease. The eagerly awaited trial of aducanumab (formerly BIIB037) did not disappoint, although much work still lies ahead.
Speaking here at AD/PD 2015: International Conferenc/.../
No comments:
Post a Comment